Lead Product(s) : BI 1467335
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Pharmaxis
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Ingelheim Discontinues Development of BI 467335 for Diabetic Retinopathy
Details : Boehringer Ingelheim decided not to further develop BI 1467335 in this indication based on the lack of a clear efficacy signal and risk of dose dependent drug interactions of the compound in NPDR patients identified in another Phase I study.
Product Name : BI 1467335
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2020
Lead Product(s) : BI 1467335
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Pharmaxis
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
